•	The adoption of restriction to reimbursement policies for less interchangeable drugs and drugs for non‐symptomatic conditions should be accompanied by impact evaluations
•	More rigorous study designs including randomization with implementation delays, health outcome evaluation, reporting of baseline characteristics, measurement over longer time periods and in a greater range of settings and drug classes as well as in combination with other pharmaceutical policies are appropriate